Virus Testing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (DFA Tests, Lateral Flow Tests, RT-PCR, Agglutination Assays, Solid-Phase Assays, Others), By Application (Influenza, Hepatitis, HIV, Measles/Rubella, Rotavirus, Others), By End User (Hospitals & Clinics, Diagnostic Centers & Laboratories, Academic & Research Institutions, O
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationVirus Testing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (DFA Tests, Lateral Flow Tests, RT-PCR, Agglutination Assays, Solid-Phase Assays, Others), By Application (Influenza, Hepatitis, HIV, Measles/Rubella, Rotavirus, Others), By End User (Hospitals & Clinics, Diagnostic Centers & Laboratories, Academic & Research Institutions, O
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 14.84 Billion |
| CAGR (2023-2028) | 5.55% |
| Fastest Growing Segment | Hepatitis |
| Largest Market | North America |
Market Overview
Global Virus Testing Kits Market has valued at USD 14.84 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.55% through 2028. The virus test kit is a diagnostic tool used to detect antibodies in infected individuals through various testing methods, including DFA, agglutinating testing, PCR, and solid-stage testing. The virus progressively affects lymphocytes, which play a vital role in the body's immune defense. Advanced technology platforms, such as enzyme-assisted nano complexes for visual identification of nucleic acids, can be designed to detect a wide range of diseases. These kits are instrumental in controlling emerging infectious diseases and high-prevalence infections. They are based on techniques commonly employed in virology laboratories for rapid antigen testing, serology, and molecular diagnostics to detect virus antibodies.
Key Market Drivers
Growing Prevalence of Infectious Diseases
The increasing global burden of rare diseases necessitates accurate diagnosis and effective treatment strategies for various chronic conditions. Developing countries such as China, India, Japan, Brazil, and other Southeast Asian nations have witnessed improved diagnosis rates due to heightened awareness of terminal illness symptoms. However, even with technologically advanced diagnostic equipment, a small margin of human error still hinders the process, resulting in a significant number of patients remaining undiagnosed at an early stage and complicating treatment. Influenza epidemics and pandemics have a profound impact on both individuals and populations. The burden of influenza varies depending on age and underlying health conditions, with high-risk patients, such as the elderly and those with pre-existing medical conditions, experiencing more frequent hospitalizations and care. As patient populations continue to grow, there is an increasing need to assess the burden of influenza, particularly due to escalating medical costs. However, accurately estimating disease prevalence can be challenging, as influenza is often mistaken for other viral illnesses, leading to under-reporting. In addition to direct costs associated with medical care, such as absenteeism and loss of work efficiency, indirect costs of influenza are substantial. Cost estimates from France, the United States, and Germany have shown that indirect costs can be five to ten times higher than direct costs. Thus, understanding the true burden of influenza is crucial for effective resource allocation and mitigation strategies.
Rising Awareness Regarding Early Diagnosis
Rising awareness regarding early diagnosis plays a significant role in increasing the demand for virus testing kits. Early diagnosis is crucial for effective disease management, outbreak control, and public health interventions. As awareness about the importance of timely testing grows, the demand for virus testing kits is expected to rise. Early diagnosis allows for timely medical intervention, which can lead to better treatment outcomes and potentially prevent disease progression or complications. In the case of infectious diseases, such as viral outbreaks, early diagnosis helps identify and isolate infected individuals promptly, reducing the spread of the virus within communities. Rapid testing and early diagnosis enable infected individuals to take appropriate precautions to prevent transmitting the virus to others, contributing to overall public health efforts. Early diagnosis aids in identifying and notifying close contacts of infected individuals, facilitating effective contact tracing and containment strategies. Timely diagnosis allows healthcare systems to allocate resources efficiently, including hospital beds, medical supplies, and healthcare personnel.
Growing Need of Rapid Detection of Diseases
The growing need for rapid detection of diseases is a key factor driving the increased demand for virus testing kits. Rapid and accurate disease detection is crucial for timely intervention, effective treatment, and public health containment efforts. Rapid detection allows for early initiation of appropriate medical treatment, which can lead to improved patient outcomes and potentially prevent disease progression or complications. For infectious diseases, rapid detection helps identify and isolate infected individuals quickly, minimizing the potential spread of the disease within communities and reducing the overall impact of an outbreak. Rapid detection enables prompt contact tracing and notification of individuals who have been in close contact with infected individuals, helping to prevent further transmission. Rapid testing is crucial in high-risk environments such as healthcare settings, where quick identification of infections can prevent the spread of diseases among patients and healthcare workers. The convergence of factors such as public health awareness, global travel, emerging diseases, and technological advancements has led to a growing recognition of the need for rapid disease detection. This recognition, in turn, is driving increased demand for virus testing kits that offer quick and accurate results, enabling timely responses to various disease threats.
Introduction of Novel Viral Testing Kits
The introduction of novel viral testing kits is a significant driver of increased demand for virus testing kits. These novel kits often bring advancements in technology, convenience, accuracy, speed, and accessibility, leading to a heightened interest in testing for various infectious diseases. Novel testing kits often utilize innovative technologies that enhance the sensitivity and specificity of virus detection, reducing the likelihood of false negatives or false positives. Many new testing kits offer rapid results, sometimes within minutes or hours, compared to traditional testing methods that might take longer. This speed is crucial for timely diagnosis and disease management. Some novel testing kits are designed for point-of-care use, enabling testing to be conducted outside of traditional healthcare settings. This accessibility expands testing reach and convenience. Novel testing kits are often designed for ease of use, making them suitable for a broader range of healthcare professionals and settings. This can lead to increased testing adoption. The introduction of home testing kits empowers individuals to test themselves in the comfort of their homes, increasing testing availability and privacy. The introduction of novel viral testing kits aligns with the increasing demand for accurate, accessible, and rapid testing solutions. As technology continues to evolve and healthcare needs evolve, these advancements contribute to a broader adoption of testing practices and a heightened emphasis on disease detection and containment.
Key Market Challenges
Lack of Awareness Across LMIC (Low- and Middle-Income Countries) Economies
The field of diagnosis distinguishes itself from other sectors of the pharmaceutical industry due to a shorter life cycle for virus diagnostic products and variations in regulatory approval methods. The diagnostic market is experiencing growth, particularly in emerging countries, driven by government initiatives to improve healthcare facilities and an increasing patient population. However, limited accessibility to diagnostic tests in emerging economies remains a challenge compared to developed economies. LMIC economies often have limited access to reliable information due to challenges such as low literacy rates, lack of internet connectivity, and limited healthcare infrastructure. This results in a lack of awareness about the importance of virus testing and the availability of testing kits. Many LMICs face challenges in providing adequate health education to their populations. As a result, individuals may not fully understand the importance of timely testing for infectious diseases.
Lack of healthcare infrastructure, including laboratories and testing facilities, can limit the availability of testing services and hinder awareness campaigns. High healthcare costs and limited access to health insurance can deter individuals from seeking testing, especially when they are not fully aware of its importance. Individuals in LMICs may have competing priorities for their limited resources, such as food, housing, and education. This can lead to healthcare taking a lower priority, including the decision to undergo testing.
Complex Regulatory Scenarios to Impede Market Growth
Stringent and complex regulatory requirements can lead to delays in obtaining approvals for new virus testing kits. This can slow down the introduction of innovative and improved testing technologies to the market. Meeting complex regulatory standards often requires significant investments in research, testing, documentation, and quality assurance processes. This can increase the cost of development and manufacturing for testing kits. Complex regulations may discourage manufacturers from investing in research and development due to the challenges associated with navigating regulatory hurdles. Different countries or regions may have varying regulatory requirements, creating challenges for manufacturers aiming to distribute their testing kits internationally. This can hinder market expansion. Smaller manufacturers or startups might find it difficult to navigate complex regulatory processes, creating barriers to entering the market. This can limit competition and innovation. Different types of virus testing kits (e.g., diagnostic, screening, surveillance) might face different regulatory pathways, creating complexity for manufacturers offering multiple products.
Key Market Trends
Emerging Economies to Offer Lucrative Growth Opportunities
Emerging economies like India, Brazil, and China present lucrative opportunities for the private health sector. Multinational companies have established their presence in these countries through partnerships or acquisitions of local diagnostic firms. In developing nations such as India, China, and Brazil, where improving living standards and an aging population drive the demand for chronic disease diagnosis and management, the disease burden is undergoing a transformation. Emerging economies offer immense potential for growth in the private health sector. The rising middle class, increased urbanization, and growing disposable incomes are driving higher demand for quality healthcare services, including diagnostics, treatments, and management of chronic diseases. Many multinational healthcare companies recognize the opportunities in these markets and are establishing their presence through strategic partnerships, collaborations, acquisitions, or investments in local diagnostic firms. This allows them to leverage local expertise and infrastructure while expanding their global footprint. Collaborating with or acquiring local diagnostic firms provides multinational companies with an understanding of local market dynamics, regulatory frameworks, and patient needs. This enables them to tailor their offerings effectively and navigate regulatory challenges. These factors collectively contribute to the promising growth prospects for manufacturers of virus diagnostic kits.
Mobile Testing Units
Mobile testing units equipped with testing facilities can reach remote and underserved areas, improving testing accessibility and coverage. Mobile testing units can overcome geographical barriers by reaching areas that are far from healthcare facilities. This ensures that individuals living in remote regions have access to testing services without the need to travel long distances. Lack of transportation infrastructure can be a major obstacle to accessing healthcare services. Mobile units eliminate the need for individuals to travel, making testing more convenient and accessible. Mobile testing units can specifically target underserved communities, which may lack proper healthcare facilities. This approach helps bridge the healthcare gap and ensures that everyone has an opportunity to get tested.
Segmental Insights
Test Type
Based on the test type, the market is segmented into DFA tests, lateral flow tests, RT-PCR, agglutination assays, solid-phase assays, and others. DFA tests dominated the market because of the use of fluorescently labelled antibodies to detect the presence of specific viral antigens. They have been used for diagnosing certain viruses, such as respiratory viruses like influenza and respiratory syncytial virus (RSV) which are commonly prevalent among the population. Moreover, RT-PCR is the rapidly growing segment in the market as nucleic acid detection is extensively utilized through the employment of polymerase chain reaction (PCR) assays. This is further supported by advancements in oligonucleotide synthesis, standardized automated procedures for nucleic acid extraction, and real-time detection of PCR products which is expected to increase the demand of RT-PCR in the upcoming years.
End User Insights
Based on end user, the market is segmented into hospitals & clinics, diagnostic centres & laboratories, academic & research institutions, and others. Hospitals and medical clinics are primary healthcare facilities where individuals seek medical attention. These settings perform various types of viruses testing to diagnose infections and guide patient treatment due to which hospitals & clinics segment is expected to dominate the market in the forecast period.
Regional Insights
North America is a dominant force in the viral test diagnostic kits market, driven by substantial investments in research and development by kit manufacturing firms, as well as the establishment of numerous testing laboratories and hospitals. The region's growing demand for viral test diagnostic kits, particularly due to the prevalence of Zika virus infections, has contributed to its market growth throughout the forecast period. Furthermore, the introduction of innovative test kits and favorable government regulations pertaining to product manufacturing are expected to provide a robust growth platform for the viral diagnostic test kits market in North America.
Recent Developments
In May 2021, Cerba HealthCare, IFC, and Proparco entered into a strategic partnership aimed at expanding diagnostic capacity and supporting pandemic response in Africa.
In August 2021, Mylab Discovery Solutions forged a technology partnership with U.S.-based Hemex Health for point-of-care (POC) diagnostics. This collaboration entails the development of test assays by Mylab, complemented by Hemex's expertise and the Gazelle POC testing platform. Notably, this initiative seeks to enhance diagnostic capabilities and drive revenue growth for companies.
In 2020, Abbott launched the "Abbott's architect i1000SR and i2000SR" laboratory instruments for Covid-19 testing. This product launch has effectively contributed to revenue growth for numerous companies.
Key Market Players
- Qiagen N.V.
- Abbott Laboratories Inc
- Thermo Fisher Scientific Inc
- Becton, Dickinson and Company
- BioMérieux SA
- Quidel Corporation
- Rapikit
- Zoetis Inc
- Luminex Corporation
- F. Hoffmann-La Roche Ltd
| By Test Type | By Application | By End User | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy